A recent study suggests that individuals who discontinue new weight-loss injections like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end traditional lifestyle programs.
Published data in a leading medical journal demonstrates that while obese individuals can lose about a fifth of their total mass while on the medication, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Users buying these treatments need to be cognizant of the risk of rapid weight regain when the treatment ends," stated lead investigator Dr. Susan Jebb.
This pace of recovery suggests a reversion to starting weight in about 18 months.
Comparing Approaches
The study, which examined dozens of studies involving over 9,000 of patients, contrasted the results of GLP-1 agonists with older methods.
The team emphasize that individuals who shed pounds through lifestyle changes alone typically see a slower weight regain—perhaps 0.1 kg a month—once they finish.
The Reason for the Quick Regain
Experts suggest the way of the jabs explains the amplified weight return.
The injections copy a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 levels far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication means appetite is uncontrolled, making excessive eating much more probable."
A Chronic Condition?
Medical guidelines advise the injections for people with weight-linked medical conditions, alongside recommended lifestyle changes.
Professionals say that, considering the likelihood of relapse, the therapy might need to be life-long.
This opinion is echoed by pharmaceutical companies, who note that the results "underscore the persistent character of excess weight," comparing it to managing diseases like hypertension.
Patient Testimonies
Users who have stopped the jabs report a powerful resurgence of appetite.
"I experienced a switch flipping and I was suddenly ravenous," said an individual.
This challenge is exacerbated if individuals have not established sustainable dietary or behavioural modifications during treatment.
Growing Use
Survey data suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is greater among women compared to males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than the NHS.
Finally, clinicians caution that while these medications are powerful agents for shedding pounds, they are not a permanent fix and lasting health benefits relies on integrated behavioural changes.
